Revolution Medicines, INC Form 4 insider transactions

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,738 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,864 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 3,058 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,294 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Xiaolin Wang, EVP of Clinical Development at Revolution Medicines, reported a gift of 2,718 shares of common stock on March 17, 2025, leaving them with 102,321 shares.

Jeff Cislini, General Counsel of Revolution Medicines, reports the acquisition of 22,000 shares of common stock and 77,000 stock options.

Chief Financial Officer of Revolution Medicines, Jack Anders, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired shares and stock options on March 1, 2025.

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports acquiring 28,600 shares of common stock and 100,100 stock options on March 1, 2025.

Chief Medical Officer of Revolution Medicines, Wei Lin, reports the acquisition of stock options and disposal of common stock related to restricted stock units.

Xiaolin Wang, an officer at Revolution Medicines, reports acquiring 19,000 shares of common stock and 66,500 stock options.

Mark A. Goldsmith, CEO of Revolution Medicines, reports acquisition of shares and options, including restricted stock units and stock options, as per a recent SEC filing.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,406 shares of common stock at $40.5 per share under a pre-arranged 10b5-1 trading plan.

Mark A. Goldsmith, President and CEO of Revolution Medicines, executed stock options and reported changes in beneficial ownership of company stock.

Margaret Horn, Chief Operating Officer of Revolution Medicines, sold 4,329 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Mark A. Goldsmith, CEO of Revolution Medicines, sold 11,714 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 4,663 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,599 shares of common stock on December 16, 2024, to cover tax obligations related to vesting restricted stock units.

Revolution Medicines' Chief Financial Officer, Jack Anders, sold 2,635 shares of common stock to cover tax obligations related to vested restricted stock units.

Director Thilo Schroeder indirectly acquired shares of Revolution Medicines through investment funds he manages, while disclaiming beneficial ownership except for pecuniary interest.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,554 shares of common stock at an average price of $55.1337, as part of a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock and exercised stock options under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Director Sushil Patel of Revolution Medicines exercised stock options and sold shares on October 31, 2024, under a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Margaret Horn, Chief Operating Officer of Revolution Medicines, exercised stock options and sold 50,000 shares of common stock on October 11, 2024, according to a recent SEC filing.

Mark A. Goldsmith, CEO of Revolution Medicines, executed stock options and sold 30,000 shares of common stock at an average price of $50.3591 per share on October 11, 2024, under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Revolution Medicines, Jack Anders, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.